retatrutide triple agonist glp-1 gip glucagon Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Why Retatrutide is different 👇

To overcome these limitations, this review discusses a range of structural modifications, including N-terminal and C-terminal substitutions, fatty acid conjugation, and large molecule fusion technologies, which have collectively contributed to enhanced half-life, increased stability, improved receptor affinity, and retained or augmented bioactivity of GLP-1 analogs

The EMA PRAC 2024 review found no causal link between licensed GLP-1 receptor agonists and suicidal ideation or self-harm, but this conclusion cannot be directly applied to retatrutide, which has additional glucagon receptor activity and lacks its own long-term safety data

[DOI] [PMC free article] [PubMed] [Google Scholar] [100].Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, et al

Discover more insights on GLP-1s by saving your virtual seat for ourwebinar with Bernstein Analyst, Alexia Howard

[DOI] [PMC free article] [PubMed] [Google Scholar] 12.Testosterone: a metabolic hormone in health and disease